



Dupixent Expands into Pediatric CSU

The FDA approved Dupixent® for children ages 2–11 with chronic spontaneous urticaria, becoming the first biologic for this population based on Phase 3 data showing reductions in itch and hives. This expansion reinforces continued movement of biologics into earlier and broader patient populations, particularly in high-burden inflammatory conditions with limited treatment options.

[Regeneron's Press Release](#)

[Sanofi's Press Release](#)

Rezpegaldesleukin in Alopecia Areata

In a Phase 2b extension study, rezpegaldesleukin (Nektar) showed increasing hair regrowth through 52 weeks in severe alopecia areata with a favorable safety profile. The durability and continued response over time highlight growing emphasis on sustained immune modulation rather than short-term induction of response.

[Read More](#)

Upadacitinib in Alopecia Areata

AbbVie submitted an FDA application for upadacitinib in severe alopecia areata, supported by Phase 3 data showing significant scalp hair regrowth, including complete responses through 52 weeks. JAK inhibition continues to strengthen its position in alopecia areata, with durability and depth of response remaining key differentiators.

[Read the Press Release](#)

ORKA-001 in Psoriasis

ORKA-001 (Oruka) demonstrated high rates of complete skin clearance (PASI 100) at 16 weeks in a Phase 2a trial with a favorable safety profile, supporting its potential as a long-acting IL-23 inhibitor. The data reflect continued differentiation in psoriasis through longer-acting mechanisms aimed at maintaining high levels of skin clearance with potentially less frequent dosing.

[Learn More](#)



ANZUPGO in Pediatric Hand Eczema

The FDA accepted LEO Pharma's sNDA for ANZUPGO® cream in adolescents with chronic hand eczema based on Phase 3 DELTA TEEN data. This submission reflects ongoing expansion of non-steroidal topical options into younger populations with chronic inflammatory skin disease and limited long-term treatment choices.

[Read More](#)

ZORYVE in Infant Atopic Dermatitis

Arcutis submitted an sNDA to expand ZORYVE® cream to infants as young as 3 months, supported by Phase 2 data showing favorable safety and early efficacy. This reflects continued focus on steroid-sparing options in very young patients, where long-term safety and tolerability are central to treatment selection.

[Learn More](#)

Across the pipeline, a consistent theme is emerging in dermatology: earlier intervention, expanding patient populations, and a growing focus on sustained, durable responses as the key measure of therapeutic value.

CPE Spotlight



The following highlights select engagements and programs supported by CPE over the past month.

Product Theater

RAPIDS (Relevant Advanced Practice Immuno-Dermatology Symposium)

- Omni, Fort Lauderdale, FL | April 23, 2026
- Dermatology-focused product theater delivered within a multi-specialty immuno-dermatology symposium
- Feedback was consistently positive, but more notably, attendees emphasized how directly applicable the content felt to patient decisions – reinforcing the value of clinically grounded formats.

Below is a list of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

Medical Affairs

Asynchronous Engagements
KOL Identification & Contracting
MOA Visualization
MSL Training
Patient Education
Poster Presentations
Scientific Platform Development

Medical Affairs + Marketing

Advisory Boards (Virtual or In-Person)
Conference Planning
Content Development
Core Slide Decks
KOL Engagements
Publications

Marketing

Branding & Visual Aids
Healthcare Event Production Management
Launch Preparation
Product Theater Planning & Logistics
Speaker Bureau Services
Speaker Training
Technical Productions

In recent product theater work, we've seen how audiences engage more with focused, clinically grounded formats that prioritize real patient application over broader discussion. At RAPIDS, this showed up clearly – audiences were more engaged with content that felt immediately applicable to patient care.

There are patterns emerging in what's resonating in dermatology product theaters right now. I'm happy to compare notes as you evaluate what's working in your own programs.

With appreciation,

Allison Goldberg, MPA
Associate Vice President
CPE Communications
Cell: 917-509-9583
agoldberg@cpeducate.com



When you're ready to explore how the CPE Communications Team can support your company, contact Allison at agoldberg@cpeducate.com